Tetracycline Should NOT Be Used for Group A Streptococcus or Streptococcus pneumoniae Infections
Tetracycline is explicitly contraindicated for treating Group A Streptococcus (GAS) infections due to high resistance rates, and it is not a recommended agent for Streptococcus pneumoniae infections. 1
Group A Streptococcus (GAS): Tetracycline is Ineffective
The IDSA guidelines are unequivocal: tetracyclines should not be used for GAS pharyngitis because of the high prevalence of resistant strains 1. This recommendation carries a strong evidence rating and reflects decades of clinical experience showing treatment failures.
Resistance Data for GAS:
- Historical resistance rates: A 1977 UK survey found 36% of GAS isolates were tetracycline-resistant, with wide geographical variation 2
- Contemporary resistance: Recent data from South Africa showed 8.3% tetracycline resistance 3, while a 2024 review noted resistance rates ranging from 22.4% in the USA to 83.7-100% in China 4
- Mechanism: Resistance is primarily mediated by tet genes, with combined tetracycline/macrolide resistance often linked to ermB insertion into transposons carrying tetM 4
What Actually Works for GAS:
The FDA label for tetracycline itself contains a critical caveat: it lists upper respiratory infections caused by Streptococcus pyogenes (GAS) as an indication but explicitly states "Tetracycline hydrochloride tablets should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible" 5. In practical terms, this means never using it empirically.
First-line treatment for GAS pharyngitis: Penicillin or amoxicillin for 10 days (strong, high-quality evidence) 1
For penicillin-allergic patients: First-generation cephalosporin (if not anaphylactically sensitive), clindamycin, clarithromycin for 10 days, or azithromycin for 5 days 1, 6
Streptococcus pneumoniae: Tetracycline is Not Recommended
While the FDA label lists lower respiratory tract infections caused by Streptococcus pneumoniae as an indication 5, tetracycline is not a preferred or recommended agent for pneumococcal infections in modern practice.
Resistance Data for S. pneumoniae:
- Historical data: A 1977 UK survey found 13% of pneumococci were tetracycline-resistant 2
- Belgian data (1996): Only 72.7% of pneumococcal isolates were susceptible to tetracycline, with an MIC₅₀ of 0.12 μg/mL 7
- Geographic variation: Resistance patterns vary widely, making empiric use problematic
What Actually Works for S. pneumoniae:
Recommended antibiotics for pneumococcal pneumonia: Macrolides, beta-lactams, and quinolones 8. These agents have superior efficacy, better pharmacokinetics, and more predictable susceptibility patterns.
Clinical Pitfalls to Avoid
Do not rely on the FDA label alone: Just because tetracycline lists streptococcal infections as indications doesn't mean it should be used. The label itself warns against empiric use for streptococcal disease 5
Geographic resistance matters: Even if local resistance data suggest some susceptibility, the risk of treatment failure with tetracycline is unacceptably high given excellent alternatives exist
Historical vs. current practice: Tetracycline may have been used historically for these infections, but antibiotic stewardship and resistance patterns have evolved. Guidelines supersede older FDA indications
Dosing is irrelevant if the organism is resistant: The FDA label specifies 500 mg four times daily for 10 days for streptococcal infections 5, but this dosing cannot overcome resistance mechanisms
The Bottom Line
For GAS infections: Use penicillin/amoxicillin as first-line. Never use tetracycline empirically. Even with documented susceptibility, better options exist that prevent rheumatic fever and suppurative complications more reliably.
For S. pneumoniae infections: Use macrolides, beta-lactams, or quinolones. Tetracycline has inferior activity, unpredictable resistance patterns, and no role in modern pneumococcal treatment algorithms.
The efficacy of tetracycline for these infections is poor to unacceptable due to widespread resistance, making it a suboptimal choice that risks treatment failure and complications including acute rheumatic fever (for GAS) and progression of pneumococcal disease.